Pliant Therapeutics (PLRX)
(Real Time Quote from BATS)
$12.81 USD
+0.28 (2.24%)
Updated Jul 23, 2024 02:28 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Pliant Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 10 | 8 | 42 | 57 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 10 | 8 | 42 | 57 |
Selling & Adminstrative & Depr. & Amort Expenses | 186 | 137 | 105 | 83 | 58 |
Income After Depreciation & Amortization | -184 | -127 | -98 | -42 | -1 |
Non-Operating Income | 24 | 5 | 0 | 0 | 1 |
Interest Expense | 1 | 1 | 0 | 0 | 0 |
Pretax Income | -161 | -123 | -97 | -42 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -161 | -123 | -97 | -42 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -161 | -123 | -97 | -42 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -187 | -127 | -96 | -40 | 0 |
Depreciation & Amortization (Cash Flow) | -3 | 0 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -184 | -127 | -98 | -42 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 42.02 | 35.85 | 21.34 | NA |
Diluted EPS Before Non-Recurring Items | NA | -2.94 | -2.71 | -1.95 | NA |
Diluted Net EPS (GAAP) | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 |
Fiscal Year end for Pliant Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.25 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.25 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 52.40 | 47.03 | 47.69 | 47.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -52.40 | -47.03 | -47.69 | -47.32 |
Non-Operating Income | NA | 5.88 | 6.25 | 6.52 | 6.46 |
Interest Expense | NA | 0.45 | 0.32 | 0.32 | 0.32 |
Pretax Income | NA | -46.96 | -41.11 | -41.49 | -41.19 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -46.96 | -41.11 | -41.49 | -41.19 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -46.96 | -41.11 | -41.49 | -41.19 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 60.18 | NA | 59.69 | 59.17 |
Diluted EPS Before Non-Recurring Items | NA | -0.78 | NA | -0.70 | -0.70 |
Diluted Net EPS (GAAP) | NA | -0.78 | -0.68 | -0.70 | -0.70 |